ODAC 30% Off Registration, Use Code: JDD30
Skip to main content
The Latest

Tirbanibulin Ointment 1% as a Novel Treatment for Actinic Keratosis: Phase 1 and 2 Results

By December 17, 2020No Comments

Featured Article

Featured Article

Current field-directed treatments of actinic keratosis (AK), a pre-malignant condition, are often limited by severe local reactions and/or complex treatment. Tirbanibulin, a novel potent anti-proliferative synthetic agent that inhibits tubulin polymerization and Src kinase signalling, is being developed as a convenient, safe, and effective field treatment of actinic keratosis.

Read more

Current field-directed treatments of actinic keratosis (AK), a pre-malignant condition, are often limited by severe local reactions and/or complex treatment. Tirbanibulin, a novel potent anti-proliferative synthetic agent that inhibits tubulin polymerization and Src kinase signalling, is being developed as a convenient, safe, and effective field treatment of actinic keratosis.

Steven Kempers MD, Janet DuBois MD, Seth Forman MD, Amy Poon BS MA, Eva Cutler BS BA, Hui Wang PhD, David Cutler MD FRCP(C), Jane Fang MD, Rudolf Kwan MBBS MRCP

 

Actinic keratosis (AK) is a pre-malignant condition, associated with prolonged ultraviolet damage predominantly on the face/scalp, trunk, and extremities. AK affects ~58 million individuals in the US, and typically occurs in males, fair-skinned individuals, and those of advancing age. As the progression of AK to invasive squamous cell carcinoma (iSCC) is unpredictable, the generally accepted approach is to treat all AK.

Current treatments are lesion- or field-directed therapies. Lesion-directed therapies are used when the lesion burden is low; but these modalities can cause scarring and long-term pigmentary changes. Field-directed therapies are used to treat multiple lesions, large areas, and subclinical lesions.

Commonly used topical treatments, while effective, frequently cause moderate-to-severe application-site reactions and deleterious effects on uninvolved skin, which are often considered unacceptable to patients. Moreover, many of these treatments have lengthy or cumbersome dosing regimens that may undermine treatment compliance and compromise efficacy.

Given the disadvantages of available topical therapies, there is a need to develop an agent that has low potential for severe local reactions, effective AK clearance, and convenient dosing.

Read Full Article Now
Article Cited in this Post

You May Also Like

Journal of Drugs in Dermatology JDD featuring video abstracts on Celebrating National Healthy Skin Month: Essential Vault Reads From JDD

Celebrating National Healthy Skin Month: Essential Vault Reads From JDD

| Featured Articles, Latest News, Skincare | No Comments
Explore high-impact research on barrier protection, photoprotection, and targeted skincare strategies to optimize lifelong skin health November is National Healthy Skin Month, making it the perfect opportunity to pull foundational…
Journal of Drugs in Dermatology JDD featuring Bruton Tyrosine Kinase Inhibitors for Systemic Lupus Erythematosus: A Systematic Review of Randomized Controlled Trials

Bruton Tyrosine Kinase Inhibitors for Systemic Lupus Erythematosus: A Systematic Review of Randomized Controlled Trials

| Featured Articles, Latest News | No Comments
Targeting BTK in Cutaneous Lupus: What New Clinical Trial Data Reveals for Dermatologists Have you explored the newest systematic review from the Journal of Drugs in Dermatology examining the potential of…
Journal of Drugs in Dermatology JDD featuring Tackling Female Hair Loss: Gentle Topicals vs. In-Office Mesotherapy

Tackling Female Hair Loss: Gentle Topicals vs. In-Office Mesotherapy

| Alopecia, Dyspigmentation, Featured Articles, Hair, Latest News, Women | No Comments
Weighing efficacy and risks across non-surgical hair restoration methods Hair restoration continues to dominate clinical inquiries, representing some of JDD's most read topics that we are bringing back out of…

Leave a Reply